Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 13/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | GFER | P55789 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 12/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814699 | 1.00 | ADRA2C (0.56) | ADRA2CMAPTGFERKDM4EGAA | |
| SCHEMBL188214 | 1.00 | ADRA2C (0.56) | ADRA2CMAPTGFERKDM4EGAA | |
| SCHEMBL81498 | 0.84 | ADRA2A (0.52) | ADRA2CADRA2AADRA2B | |
| SCHEMBL17898055 | 0.84 | ADRA2A (0.52) | ADRA2CADRA2AADRA2B | |
| SCHEMBL10293570 | 0.84 | ADRA2A (0.52) | ADRA2CADRA2AADRA2B | |
| SCHEMBL24352439 | 0.83 | ADRA2A (0.43) | ADRA2CESR2ADRA2AADRA2BL3MBTL1 | |
| SCHEMBL25839419 | 0.83 | ADRA2A (0.43) | ADRA2CESR2ADRA2AADRA2BL3MBTL1 | |
| SCHEMBL29310072 | 0.83 | ADRA2A (0.43) | ADRA2CESR2ADRA2AADRA2BL3MBTL1 | |
| SCHEMBL15858055 | 0.82 | ADRA2A (0.52) | ADRA2CKDM4EGAAESR2ADRA2A | |
| SCHEMBL31276581 | 0.82 | ADRA2A (0.44) | ADRA2CESR2ADRA2AADRA2BESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566612-A2 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3762385-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2024-11-28 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117720541-A | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-111902413-B | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones | 里科瑞尔姆IP控股有限责任公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | RECURIUM IP HOLDINGS, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | MKI67, BRCA1, CCNI | ADRA2C 1173/4885MAPT 2838/4885GFER 4800/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | ADRA2C 1173/4885MAPT 2838/4885GFER 4800/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | ADRA2C 1173/4885MAPT 2838/4885GFER 4800/4885 |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | ADRA2C 1173/4885MAPT 2838/4885GFER 4800/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | ADRA2C 1807/4885MAPT 4723/4885GFER 1162/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | ADRA2C 4757/4885MAPT 3813/4885GFER 3024/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | ADRA2C 3051/4885MAPT 3466/4885GFER 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.